JJJanni Majgaard Jensen

Janni Majgaard Jensen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Janni Majgaard Jensen has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Anne Skakkebæk

    Department of Clinical Genetics, Aarhus University Hospital, Aarhus, Denmark

    1 shared publication
  • Charlotte K. Lautrup

    Department of Clinical Genetics, Aarhus University Hospital, Aarhus, Denmark

    1 shared publication
  • Christine Wandall-Frostholm

    Department of Biomedicine, Pulmonary and Cardiovascular Pharmacology, Aarhus University, Aarhus, Denmark

    1 shared publication
  • Erling Bjerregaard Pedersen

    University Clinic in Nephrology and Hypertension, Regional Hospital West Jutland and Aarhus University, Laegaardvej 12J, DK-7500, Holstebro, Denmark

    1 shared publication
  • Frank Holden Mose

    Department of Clinical Medicine, Aarhus University, 8000 Aarhus, Denmark

    1 shared publication
  • Hans Gjørup

    Department of Oral and Maxillofacial Surgery, Resource Centre for Oral Health in Rare Medical Conditions, Aarhus University Hospital, Aarhus, Denmark

    1 shared publication

Latest Publications

  • Familial colorectal cancer and tooth agenesis caused by an AXIN2 variant: how do we detect families with rare cancer predisposition syndromes?

    by Janni M. Jensen, Anne Skakkebæk, Mette Gaustadness, Mette Sommerlund, Hans Gjørup, Ken Ljungmann, Charlotte K. Lautrup, Lone Sunde

    We present a three-generation family with an AXIN2 variant and a family history of colorectal cancer (CRC), colon polyps and tooth agenesis. A likely pathogenic variant was detected in the AXIN2 gene (c.1994dup; p.(Asn666Glnfs*41)). This variant has previously been associated with tooth agenesis and polyposis, only. In this case report we describe eight carriers with tooth agenesis and variable clinical findings, including polyps and CRC. Our case provides additional knowledge to the sparse data on genotype–phenotype association related to AXIN2 associated cancer syndrome. Further, our case highlights the importance of analysing an extended CRC and oligodontia/ectodermal dysplasia gene panel including AXIN2 but also raises awareness and discussion about appropriate surveillance program.


  • Open Access

    Effect of sodium nitrite on renal function and sodium and water excretion and brachial and central blood pressure in healthy subjects: a dose-response study

    by Jeppe Bakkestroem Rosenbaek, Safa Al Therwani, Janni Majgaard Jensen, Frank Holden Mose, Christine Wandall-Frostholm, Erling Bjerregaard Pedersen, Jesper Noergaard Bech

    Sodium nitrite (NaNO2) is converted to nitric oxide (NO) in vivo and has vasodilatory and natriuretic effects. Our aim was to examine the effects of NaNO2on hemodynamics, sodium excretion, and glomerular filtration rate (GFR). In a single-blinded, placebo-controlled, crossover study, we infused placebo (0.9% NaCl) or 0.58, 1.74, or 3.48 μmol NaNO2·kg−1·h−1for 2 h in 12 healthy subjects, after 4 days of a standard diet. Subjects were supine and water loaded. We measured brachial and central blood pressure (BP), plasma concentrations of renin, angiotensin II, aldosterone, arginine vasopressin (P-AVP), and plasma nitrite (P-[ ]), GFR by Cr-EDTA clearance, fractional excretion of sodium (FENa) free water clearance (CH2O), and urinary excretion rate of guanosine 3′,5′-cyclic monophosphate (U-cGMP). The highest dose reduced brachial systolic BP (5.6 mmHg, P = 0.003), central systolic BP (5.6 mmHg, P = 0.035), and CH2O(maximum change from 3.79 to 1.27 ml/min, P = 0.031) and increased P-[ ] (from 0.065 to 0.766 μmol/l, P < 0.001), while reducing U-cGMP (from 444 to 247 pmol/min, P = 0.004). GFR, FENa, P-AVP, and the components in the renin-angiotensin-aldosterone system did not change significantly. In conclusion, intravenous NaNO2induced a dose-dependent reduction of brachial and central BP. The hemodynamic effect was not mediated by the renin-angiotensin-aldosterone system. NaNO2infusion resulted in a vasopressin-independent decrease in CH2Oand urine output but no change in urinary sodium excretion or GFR. The lack of increase in cGMP accompanying the increase in [ ] suggests a direct effect of nitrite or nitrate on the renal tubules and vascular bed with little or no systemic conversion to NO.